

AM100151 P1
PATENTDECLARATION AND POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name:

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled Branched Adamantyl and Noradamantyl Aryl- and Aralkylpiperazines with Serotonin 5-HT1A Activity, the specification of which

(check one) _____ is attached hereto.

_____ was filed on _____ as
Application Serial No. _____
and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority Claimed
Yes No

(Number) (Country) (Day/Month/Year Filed)

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States Provisional Application(s) for Patent listed below:

60/228,820 November 12, 1999 which was converted from U.S. Patent Application
(Provisional Appln. No.) (Filing Date) No. 09/439,798, filed November 12, 1999, pursuant
to a petition filed under 37 C.F.R. 1.53(c)(2)(i).

Not Yet Known November 18, 1999 which was converted from U.S. Patent Application
(Provisional Appln. No.) (Filing Date) No. 09/442,981, filed November 18, 1999, pursuant
to a petition filed under 37 C.F.R. 1.53(c)(2)(i).

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States Application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

AM100151 P1
PATENT

_____ (Application Serial No.)	_____ (Filing Date)	Pending (Status - Patented, pending, abandoned)
_____ (Application Serial No.)	_____ (Filing Date)	(Status - Patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Egon E. Berg, Reg. No. 21,117, of One Campus Drive, Parsippany, New Jersey, 07054; and Rebecca R. Barrett, Reg. No. 35,152; Steven R. Eck, Reg. No. 36,126; Arnold S. Mitowsky, Reg. No. 35,288; Michael R. Nagy, Reg. No. 33,432; George Tarnowski, Reg. No. 27,472; all of P.O. Box 8299, Philadelphia, Pennsylvania, 19101; Daniel B. Moran, Reg. No. 41,204 of 401 N. Middletown Road, Pearl River, New York, 10965; and Barbara L. Lences, Reg. No. 41,148, of CN-8000, Princeton, New Jersey, 08543-8000.

Address all telephone calls to Steven R. Eck at telephone number (610) 902-2628.

Address all correspondence to Egon E. Berg, American Home Products Corporation, Patent Law Department - 2B, One Campus Drive, Parsippany, New Jersey, 07054.

Full name of sole or first inventor Wayne E. Childers, Jr.

Inventor's signature Wayne E. Childers, Jr. 10/27/00
Date

Residence 201 Riverwood Drive, New Hope, Pennsylvania, 18938

Citizenship United States of America

Post Office Address Same as residence

Full name of second joint inventor, if any Horace Fletcher, III

Inventor's signature Horace Fletcher, III 11/1/00
Date

Residence 2382 Schaffer Road, Portstown, Pennsylvania, 19464

Citizenship United States of America

Post Office Address Same as residence

AM100151 P1
PATENT

Full name of third joint inventor, if any Mazid A. Abou-Gharbia
Inventor's signature *Mazid A. Abou-Gharbia* Date 10/27/00
Residence 26 Hawthorne Drive, Princeton Junction, New Jersey, 08550
Citizenship United States of America
Post Office Address Same as residence

Full name of fourth joint inventor, if any John P. Yardley
Inventor's signature *John P. Yardley* Date 10/06/00
Residence 134 Hughes Road, King of Prussia, Pennsylvania, 19406
Citizenship United States of America
Post Office Address Same as residence

23 October 2000
1ED1:OCO:SRE
AM100151 01
PATENT

- 1 -

5 **BRANCHED ADAMANTYL AND NORADAMANTYL ARYL- AND
ARALKYLPIPERAZINES WITH SEROTONIN 5-HT_{1A} ACTIVITY**

 This application claims the benefit of U.S. Provisional Application No.
60/228,820, which was converted from U.S. Patent Application No. 09/439,798, filed
10 November 12, 1999; and U.S. Provisional Application No. Not Yet Known, filed
November 18, 1999, which was converted from U.S. Patent Application No.
09/442,981, pursuant to a petition filed under 37 C.F.R. 1.53(c)(2)(i).

 This invention relates to novel branched adamantyl, noradamantyl aryl and
15 aralkylpiperazines having serotonin 5-HT_{1A} activity. More particularly, the present
invention relates to compounds and methods using them to provide neuroprotection
and prevent, inhibit or limit processes of neurodegeneration in mammals.

Introduction

20 Compounds having selective agonist and partial agonist activity at the 5-HT_{1A}
receptor have established a presence in the marketplace as effective anxiolytic agents
(buspirone, Buspar[®], US Patent 3,717,634). Evidence generated over the past 20
years supports the hypothesis that 5-HT_{1A} agonists and partial agonists may find use
25 in the treatment of several diseases such as anxiety, depression, schizophrenia, sexual
dysfunction, cognitive deficits resulting from neurodegenerative diseases like
Alzheimer's Disease, nausea and vomiting, sleep disorders, pain, obesity, pain,
addiction/withdrawal and in the treatment of prostate cancer (for recent reviews, see:
Rasmussen, K. and Rocco, V. P., Recent Progress in Serotonin (5-HT)_{1A} Receptor
30 Modulators, In: *Annual Reports in Medicinal Chemistry, Volume 30*, Bristol, J. A.,
ed., Academic Press, New York, 1995, pp. 1-9; Schaus, J. M. and Bymaster, F. P.,
Latest Developments in Serotonin Receptor Modulation, In: *Annual Reports in
Medicinal Chemistry, Volume 33*, Bristol, J. A., ed., Academic Press, New York,
1998, pp. 21-30).

35 More recent evidence now indicates that 5-HT_{1A} agonists and partial agonists
act in other disease states and conditions by virtue of their ability to inhibit the release
of glutamate. 5-HT_{1A} agonists and partial agonists may be used to treat conditions